Summit Therapeutics to participate in BTIG Healthcare Conference

Drug discovery and development company Summit Therapeutics announced on Friday that its management would participate in one-on-one meetings at the 2018 BTIG Healthcare Conference.

The AIM-traded firm said the conference was being held on 27 February in Snowbird, Utah.

“Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies,” the board said of its current focus.

“Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection.”